A Safety and Efficacy Study of Duvelisib in Relapsed/Refractory Follicular Lymphoma (Q113912502)
Jump to navigation
Jump to search
clinical trial
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A Safety and Efficacy Study of Duvelisib in Relapsed/Refractory Follicular Lymphoma |
clinical trial |
Statements
A Phase 2, Single Arm, Open Label, Multi-center Clinical Study of Dual PI3K-δ,γ Inhibitor Duvelisib in Patients With Relapsed/Refractory Follicular Lymphoma (English)
0 references
18 December 2019
0 references
31 October 2021
0 references
24
0 references
18 year
0 references